Evidence map›Paper›PMID 26382603›Full record

ArticleVaccine2015

Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.

Subhashini Jagu, Balusubramanyam Karanam, Joshua W Wang, Hatem Zayed, Margit Weghofer, Sarah A Brendle, Karla K Balogh, Kerstin Pino Tossi, Richard B S Roden, Neil D Christensen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Subhashini JaguDepartment of Pathology, The Johns Hopkins University, Baltimore, MD, USA.
Balusubramanyam KaranamDepartment of Pathology, The Johns Hopkins University, Baltimore, MD, USA.
Joshua W WangDepartment of Pathology, The Johns Hopkins University, Baltimore, MD, USA.
Hatem ZayedBiomedical Sciences Program, Health Sciences Department, Qatar University, PO Box 2713, Doha, Qatar.
Margit WeghoferMedigene AG, Pannegg/Martinsreid, Germany.
Sarah A BrendleJake Gittlen Cancer Research Foundation, Pennsylvania State University College of Medicine, Hershey, PA, USA; Department of Pathology, Pennsylvania State University College of Medicine, Hershey, PA, USA.
Karla K BaloghJake Gittlen Cancer Research Foundation, Pennsylvania State University College of Medicine, Hershey, PA, USA; Department of Pathology, Pennsylvania State University College of Medicine, Hershey, PA, USA.
Kerstin Pino TossiMedigene AG, Pannegg/Martinsreid, Germany.
Richard B S RodenDepartment of Pathology, The Johns Hopkins University, Baltimore, MD, USA; Department of Oncology, The Johns Hopkins University, Baltimore, MD, USA; Department of Gynecology and Obstetrics, The Johns Hopkins University, Baltimore, MD, USA.
Neil D ChristensenJake Gittlen Cancer Research Foundation, Pennsylvania State University College of Medicine, Hershey, PA, USA; Department of Pathology, Pennsylvania State University College of Medicine, Hershey, PA, USA; Department of Microbiology and Immunology, Pennsylvania State University College of Medicine, Hershey, PA, USA. Electronic address: ndc1@psu.edu.
Johns Hopkins University · USMedigene (Germany) · DEPennsylvania State University · USCancer Research Foundation · USQatar University · QA

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI TZYY-CHOOU WU · 2003 to 2026
$53.5M
Mechanisms of Papillomavirus NeutralizationR01CA118790 · NCI · JOHNS HOPKINS UNIVERSITY · PI RODEN, RICHARD BRUCE · 2007 to 2018
$2.9M
NCI NIH HHS CA118790NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA098252NCI NIH HHS P50 P50CA098252NCI NIH HHS R01 CA118790
6 · The paper itself

Abstract

Vaccination with the minor capsid protein L2, notably the 17-36 neutralizing epitope, induces broadly protective antibodies, although the neutralizing titers attained in serum are substantially lower than for the licensed L1 VLP vaccines. Here we examine the impact of other less reactogenic adjuvants upon the induction of durable neutralizing serum antibody responses and protective immunity after vaccination with HPV16 and HPV31 L2 amino acids 17-36 inserted at positions 587 and 453 of VP3, respectively, for surface display on Adeno-Associated Virus 2-like particles [AAVLP (HPV16/31L2)]. Mice were vaccinated three times subcutaneously with AAVLP (HPV16/31L2) at two week intervals at several doses either alone or formulated with alum, alum and MPL, RIBI adjuvant or Cervarix. The use of adjuvant with AAVLP (HPV16/31L2) was necessary in mice for the induction of L2-specific neutralizing antibody and protection against vaginal challenge with HPV16. While use of alum was sufficient to elicit durable protection (>3 months after the final immunization), antibody titers were increased by addition of MPL and RIBI adjuvants. To determine the breadth of immunity, rabbits were immunized three times with AAVLP (HPV16/31L2) either alone, formulated with alum±MPL, or RIBI adjuvants, and after serum collection, the animals were concurrently challenged with HPV16/31/35/39/45/58/59 quasivirions or cottontail rabbit papillomavirus (CRPV) at 6 or 12 months post-immunization. Strong protection against all HPV types was observed at both 6 and 12 months post-immunization, including robust protection in rabbits receiving the vaccine without adjuvant. In summary, vaccination with AAVLP presenting HPV L2 17-36 epitopes at two sites on their surface induced cross-neutralizing serum antibody, immunity against HPV16 in the genital tract, and long-term protection against skin challenge with the 7 most common oncogenic HPV types when using a clinically relevant adjuvant.

Indexed as

Adjuvants, ImmunologicAnimalsAntibodies, NeutralizingAntibodies, ViralCapsid ProteinsDependovirusDisease Models, AnimalEpitopesFemaleHuman papillomavirus 16MiceMice, Inbred BALB COncogene Proteins, ViralPapillomaviridaePapillomavirus InfectionsPapillomavirus VaccinesAdjuvants, ImmunologicAntibodies, NeutralizingAntibodies, ViralCapsid ProteinsEpitopeshuman papillomavirus vaccine, L1 type 16, 18L2 protein, Human papillomavirus type 16Oncogene Proteins, Viraloncogene viral capsid protein L2, human papillomavirus type 33Papillomavirus VaccinesVaccines, SyntheticAAV2Adeno-associated virusAdjuvantChallengeDisplayHPV16HPV31Human papillomavirusL2Neutralizing antibodyVaccineVLP

Identifiers

PMID26382603
PMCPMC4763949
OpenAlexW1688784376

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.